Responses

Download PDFPDF

Quality and safety for substances of human origins: scientific evidence and the new EU regulations
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    The SoHO Regulation: Aligning National and European objectives in the interests of Patients

    Dear editor,

    Both the commentary from Elias et al, “Quality and safety for substances of human origins: scientific evidence and the new EU regulations”, and the response to that commentary from Domínguez-Gil et al, recently published in BMJ Global Health (1) caught our attention. The response from Domínguez-Gil et al eloquently explains the recommitment to the principle of voluntary and unpaid donation in the new SoHO Regulation(2) and comprehensively addresses several statements in the commentary from Elias et al which required clarification. Some additional items in the commentary are addressed here.

    The commentary states that “in Europe, countries allowing monetary compensation for donors are the only ones achieving self-sufficiency in plasma collection for the production of immunoglobulin.’ While four countries collect more plasma than they theoretically need to meet their patients’ current needs (Austria, Czechia, Germany, and Hungary) the finished plasma-derived medicines, including Immunoglobulins, are dispatched to those countries where the company markets these products, independently from the origin of the plasma.(3,4) Czechia is noteworthy because its blood and plasma collection systems generate the highest per capita collection globally,(5) including a high volume of plasma collected in public hospitals. Concurrently, immunoglobulin provision in this same country is below half of the average per capita usage for this product across the EU, and yet...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    VOLUNTARY AND UNPAID DONATION OF SUBSTANCES OF HUMAN ORIGIN: A FUNDAMENTAL PRINCIPLE OF THE EU REGULATION
    • Beatriz Domínguez-Gil, Director General Organización Nacional de Trasplantes. Ministry of Health of Spain
    • Other Contributors:
      • Aránzazu De Celis, Technical advisor
      • Nuria García-Escribano, Technical advisor
      • Dolores Hernández Maraver, Medical advisor
      • Rosario Marazuela, Medical advisor
      • Inmaculada Navarro, Health Counsellor

    Dear Editor

    We have read with interest the paper from Elias JJ et al. on the Regulation on standards of quality and safety for substances of human origin intended for human application (SoHO).(1,2) The authors properly highlight two main objectives of the SoHO Regulation, namely, ensuring the safety (and quality) of SoHO for clinical use and strengthening the sufficiency in supply of what the Regulation defines as critical SoHO, an objective particularly relevant to the availability of plasma-derived therapeutic products. However, we would like to correct some inaccuracies and explain our insights on voluntary and unpaid donation (VUD).

    First, the final text of the SoHO Regulation was adopted by the European Parliament on 24 April 2024 and the European Council is scheduled to formally adopt it later this month. Once adopted by the co-legislators and published in the Official Journal of the European Union (EU), the Regulation will enter into force and Member states (MS) will need to implement its provisions by 2027. Therefore, and contrary to what stated by the authors, the adopted text is no longer open to debate or amendments.

    Second, the principle of VUD is not newly established by the Regulation, but already reflected in Directive 2002/98/EC on blood and blood components (3) and Directive 2004/23/EC on tissues and cells,(4) in alignment with the EU Charter of Fundamental Rights. The Charter enshrines the fundamental principle of human dignity and,...

    Show More
    Conflict of Interest:
    None declared.